|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
MARCH 12, 2007
SuperGen Is Looking Healthier  Biotechs are gaining traction this year as fund managers discover many with viable products that are still underpriced. One is SuperGen (SUPG
) (SUPG), whose drugs target solid tumors, blood disorders, and hematological malignancies. Now trading at 4.78, SuperGen has inked a pact with Johnson & Johnson (JNJ
) to market its Food & Drug Administration-approved drug Dacogen--for myelodysplastic blood disorder syndrome--outside North America. To start, J&J plans to focus on Europe and Japan. In the U.S., Dacogen is marketed by MGI Pharma (MOGN
), which owns 9% of SuperGen. Dacogen's U.S. 2006 sales totaled $36 million, beating even the company's estimate of $25 million. For 2007, Dacogen sales will hit $120 million, figures Elemer Piros of Rodman & Renshaw, who rates the stock a buy, with a 12-month target of 24. SuperGen's own estimate is a more modest $100 million. Its royalties from MGI will grow as sales expand, so Piros expects MGI to buy SuperGen at some point. Vinny Jindal of ThinkEquity Partners also rates SuperGen a buy, but with a much lower 12-month target of 8. He expects to see an uptick in Dacogen sales in the first quarter.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2007, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version